 NSCLC: ctDNA data in stage I-III patients showed 82 detection pre-treatment and was able to identify 100 of relapses prior to radiographic imaging 5.4 mo lead time Breast Cancer: Data from the largest longitudinal ctDNA cohort to date 1100 samples showed Signateras ability to detect recurrence with high accuracy across all subtypes Renal Cell: ctDNA dynamics were predictive of treatment outcome in metastatic RCC patients receiving targeted therapy TKI, after just 6 weeks Merkel Cell: First data showing the ability of Signatera as a surveillance tool in MCC patients regardless of MCPyV status AUSTIN, Texas , May 31, 2022 PRNewswire -- Natera, Inc. NASDAQ: NTRA, a global leader in cell-free DNA testing, today announced that new data on its personalized and tumor-informed molecular residual disease MRD test, Signatera, will be presented at the 2022 ASCO Annual Meeting taking place June 3 7, 2022. There will be seven poster presentations and one oral presentation highlighting the prognostic and predictive value of its personalized MRD technology in a wide range of tumors. 